1
Home
Companies

Lumos Pharma

#9725

Rank

$37.54M

Marketcap

US United States

Country

Lumos Pharma
Leadership team

Ms. Lori D. Lawley CPA (CFO & Principal Accounting Officer)

Mr. Richard J. Hawkins (CEO & Chairman)

Dr. John C. McKew Ph.D. (Chief Scientific Officer & Pres)

Products/ Services
Biopharma, Biotechnology, Clinical Trials, Health Care, Pharmaceutical
Headquarters
Austin, Texas, United States
Established
2014
Company Registration
SEC CIK number: 0001126234
Revenue
500K - 2M
Traded as
LUMO
Social Media
URL
https://www.lumos-pharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
History

Founded in 2015, Lumos Pharma is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for rare diseases. We are actively advancing our portfolio of innovative small molecule programs and are dedicated to working collaboratively to bring novel therapies to patients with rare diseases.

Mission
We are dedicated to advancing treatments for rare diseases through innovative science and developing transformative therapies that provide meaningful impact on the lives of those living with rare diseases.
Vision
Our vision is to develop and bring transformative therapeutic options that have lasting, positive impacts on the quality of life for individuals living with rare diseases.
Key Team

Mr. Carl W. Langren (Consultant)

Lisa Miller (Sr. Director of Investor Relations)

Mr. Aaron Schuchart B.B.A., CPA, M.B.A. (Chief Bus. Officer)

Dr. David B. Karpf B.A., M.D. (Chief Medical Officer)

Mr. Bradley J. Powers J.D. (Chief Compliance Officer & Gen. Counsel)

Mr. Eddie L. Varnado M.B.A. (VP of Fin. & Corp. Controller)

Recognition and Awards
Lumos Pharma has been recognized multiple times by the financial and industry press and has also been named as one of the “50 Most Innovative Companies in Biotech” by Fortune Magazine in 2020.
References

https://in.investing.com/equities/newlink-genetics-company-profile

https://finance.yahoo.com/quote/LUMO/profile?p=LUMO

https://www.crunchbase.com/organization/lumos-pharma

https://companiesmarketcap.com/

https://www.lumos-pharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Lumos Pharma
Leadership team

Ms. Lori D. Lawley CPA (CFO & Principal Accounting Officer)

Mr. Richard J. Hawkins (CEO & Chairman)

Dr. John C. McKew Ph.D. (Chief Scientific Officer & Pres)

Products/ Services
Biopharma, Biotechnology, Clinical Trials, Health Care, Pharmaceutical
Headquarters
Austin, Texas, United States
Established
2014
Company Registration
SEC CIK number: 0001126234
Revenue
500K - 2M
Traded as
LUMO
Social Media
URL
https://www.lumos-pharma.com